ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 257

Meta-Analysis of Four 12-Week Phase III Clinical Trials Investigating the Effect of TDT 064, a Transdermal Gel, in Osteoarthritis of the Knee

Matthias Rother1, Johannes C. Vester2, Wolfgang W. Bolten3 and Philip G. Conaghan4, 1IMR Partner GmbH, Graefelfing, Germany, 2IDV Data Analysis and Study Planning, Krailling, Germany, 3Rheumatology, Klaus-Miehlke-Klink, Wiesbaden, Germany, 4University of Leeds, Leeds, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: clinical trials, Knee, meta-analysis and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: A transfersome is an ultradeformable lipid vesicle originally developed to deliver high concentrations of drug (eg NSAIDs) transdermally. Large interventional trials in osteoarthritis (OA) of the knee comparing ketoprofen-containing vesicles (IDEA-033) to vesicles without active drug (called Sequessome, TDT 064) showed conflicting results for IDEA-0331-3 but all demonstrated pronounced treatment effects of the vehicle itself (TDT 064) that, in one study,4 were comparable to 100 mg b.i.d. celecoxib and statistically significantly superior to oral placebo.4 Objectives were to investigate how the treatment effects seen with TDT 064 compare with the results reported for the placebo arm of other OA interventional studies using a meta-analytic approach.

Methods: The efficacy of TDT 064 gel has been evaluated in four randomized, double-blind, parallel-group multicenter, 12-week Phase III studies of IDEA-033 in knee OA that included TDT 064 as a drug-free vesicle control group. The meta-analysis combines the results of the WOMAC pain subscales from the studies which were standardized to a 0–100 scale. The resulting pre-post effect size (ES) is the standardized difference (Cohen)5 of the changes from baseline of the WOMAC pain subscale score at Week 12 (based on the standard deviation of the changes of the corresponding TDT 064 group). Effect sizes of 0.2, 0.5, and 0.8 are used to represent small, medium, and large effect sizes, respectively.5 The results of the meta-analysis are presented as two-sided tests with two-sided 95.0% confidence intervals (CIs; Hedges’g). The results of this analysis are compared with those of a meta-analysis of placebo responses from other conventional trials as published by Zhang et al.6

Results: The ES calculated for a total of 1061 patients with OA of the knee treated with TDT 064 gel was 1.15 (CI: 1.09–1.21). The respective values for the individual 4 studies were 1.33 (CI: 1.18–1.47)1, 1.12 (CI: 1.03–1.21)2, 1.05 (CI: 0.87–1.24)3, and 1.12 (CI: 1.00–1.24)4. The results were comparable irrespective of whether 2.2 g or 4.4 g of TDT 064 gel was used (ES 2.2 g: 1.17 [CI: 1.07–1.28]; ES 4.4 g: 1.12 [CI: 1.04–1.20]). This compares to an ES of 0.51 (CI: 0.46–0.55) reported for all placebo applications and an ES of 0.63 (CI: 0.47–0.80) for the topical placebo arm investigated with topical formulations in the meta-analysis of Zhang et al.6

Conclusion: Pain reduction reported in 4 comparative, double-blind studies in knee OA using TDT 064 is substantially higher than the reduction reported for the topical placebo arm of other interventional trials. The magnitude of the difference indicates that this effect is unlikely to be due to a placebo response alone. 

References

  1. Stucki G, et al. Ann Rheum Dis 2007;66(Suppl. II):510.
  2. Rother M, et al. EULAR Annual European Congress of Rheumatology 2012. Abst #12-3375.
  3. Rother M, et al. EULAR Annual European Congress of Rheumatology 2012. Abst #12-3378.
  4. Conaghan P, et al. EULAR Annual European Congress of Rheumatology 2012. Abst #12-3366.
  5. Cohen J. Statistical power analysis for the behavioural sciences (2nd ed). Lawrence Erlbaum Associate Publishers: Hillsdale, NJ (1988).
  6. Zhang W, et al. Ann Rheum Dis 2008;67:1716-23.

Disclosure:

M. Rother,

Pro Bono Bio Entrepreneur Ltd.,

5,

IDEA AG,

3;

J. C. Vester,
None;

W. W. Bolten,
None;

P. G. Conaghan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/meta-analysis-of-four-12-week-phase-iii-clinical-trials-investigating-the-effect-of-tdt-064-a-transdermal-gel-in-osteoarthritis-of-the-knee/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology